Ryvu Therapeutics S.A.

Warsaw Stock Exchange RVU.WA

Ryvu Therapeutics S.A. EBITDA for the year ending December 31, 2023: USD -20.55 M

Ryvu Therapeutics S.A. EBITDA is USD -20.55 M for the year ending December 31, 2023, a -38.09% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.

Ryvu Therapeutics S.A. EBITDA for the year ending December 31, 2022 was USD -14.88 M, a 8.79% change year over year.
Ryvu Therapeutics S.A. EBITDA for the year ending December 31, 2021 was USD -16.32 M, a -241.03% change year over year.
Ryvu Therapeutics S.A. EBITDA for the year ending December 31, 2020 was USD -4.78 M, a 49.10% change year over year.
Ryvu Therapeutics S.A. EBITDA for the year ending December 31, 2019 was USD -9.40 M, a -104.05% change year over year.

Key data

Date	EBITDA	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)

Warsaw Stock Exchange: RVU.WA

Ryvu Therapeutics S.A.

CEO	Mr. Pawel Tadeusz Przewiezlikowski M.B.A., M.Sc.
IPO Date	July 14, 2011
Location	Poland
Headquarters	Leona Henryka Sternbacha 2
Employees	270
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Ryvu Therapeutics S.A., a clinical stage biopharmaceutical company, engages in developing of novel small molecule therapies for treatment in oncology. Its lead candidate, RVU120, is a CDK8 kinase inhibitor with potential for development in hematological malignancies and solid tumors, which is in Phase 1b study for the treatment of acute myeloid leukemia and myelodysplastic syndrome. The company's products also include SEL24/MEN1703, a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group that is in Phase 2 clinical trial for the treatment of acute myeloid leukemia. In addition, its early pipeline candidates include candidates in the area of kinases, cancer metabolism, synthetic lethality, and immuno-oncology. Ryvu Therapeutics S.A. was founded in 2007 and is headquartered in Kraków, Poland.

Key trends

Past 5 years